Topical Dapsone 5% Gel
Acneiform Dermatitis
Memorial Sloan Kettering Cancer CenterPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Acneiform Dermatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
lut014 Lutris Pharma Ltd. | Phase 2 | NR |
Same molecule, other indications
Topical Dapsone 5% Gel is also rated in:
Metastatic Colorectal Cancer or Head and Neck Squamous Cell CarcinomaDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →